|
Apr 23
|
Bullish Clene Insiders Loaded Up On US$9.58m Of Stock
|
|
Apr 16
|
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
|
|
Mar 19
|
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
|
|
Mar 15
|
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
|
|
Mar 13
|
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
|
|
Mar 7
|
Clene to Present at the 36th Annual ROTH Conference
|
|
Feb 5
|
Clene Inc. announces positive results from CNM-Au8 results from MS trial
|
|
Jan 24
|
Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment
|
|
Jan 10
|
Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial
|
|
Jan 3
|
Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3
|
|
Dec 22
|
Clene Announces New Data from HEALEY ALS Platform Trial
|
|
Dec 21
|
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
|
|
Dec 21
|
Clene Provides Update on ALS Clinical Development Meeting With FDA
|
|
Dec 19
|
How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
|
|
Dec 8
|
Nobel Prize in Chemistry's Spotlight on Nanotechnology Shines Light on Clene Efforts to Develop Catalytically Active Nanoparticles
|
|
Nov 15
|
Insider Spends US$103k Buying More Shares In Clene
|
|
Nov 14
|
Clene Among Grant Awardees Selected to Advance Scientific Research on ALS
|
|
Nov 9
|
Clene Announces Q3 2023 Financial Results, Operating Highlights
|
|
Nov 7
|
Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45. ...
|
|
Nov 7
|
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
|